First Quarter 2023 Earnings

revvity

May 11, 2023

Safe Harbor

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, plans concerning business development opportunities, acquisitions or divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlink and is available on the “Financial Information” section of our website at www.revvity.com.

Key Takeaways

Portfolio Transformation	Launch Of Revvity	1Q Results
Successfully **completed divestiture of Analytical and Enterprise Solutions business** to New Mountain Capital and begun capital deployment activities.	Global **launch of the company as Revvity**, Inc. Stock ticker to change to "RVTY" on May 16th.	1Q Non-COVID organic growth and adjusted EPS at the **upper-end of expectations**

A Scientific Solutions Company Helping To Solve The World's Greatest Health Challenges From Discovery To Development, and Diagnosis to Cure

Q123 Revenue Highlights

Segments

Diagnostics · Life Sciences



Geographic

AMERICAS · APAC · EU



Product Mix

RECURRING · NON-RECURRING



Revenue performance provided on a non-COVID organic basis

Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

1Q23 Financial Results

ADJUSTED REVENUE	ADJUSTED OP MARGIN	ADJUSTED EPS	NON-GAAP FREE CASH FLOW
$675M	28.0%	$1.01	$51M
⬇ -30% y/y	⬇ -1,280bps y/y	⬇ -56% y/y	⬇ -63% y/y
Organic: -27% | M&A: 0% | FX: -3%	**Adj. Gross Margin:** 62.4% | -510bps y/y	**Adj. Tax Rate:** 21.5%	Includes **$80M** of AES & pension related outflows
Non-COVID: +6% organic growth		**Adj. Net Interest & Other:** $27M	
COVID: $3M vs. $310M in 1Q'22			

revvity

Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our website and in this hyperlink

Life Sciences

Product



REVENUE	AJUSTED OP MARGINS
+9% Organic Growth	39.4%
Reported: 7% | M&A: 0% | FX: -2%	+340bps y/y

- +MSD growth from Pharma/Biotech, +DD growth from Academic/Gov’t
- Consistent +DD reagents organic growth
- Software in line with expectations due to timing of multi-year renewals, +DD organic growth on 2 & 3-year average

Diagnostics

End Market

IMMUNODX | REPRODUCTIVE HEALTH | APPLIED GENOMICS



REVENUE	AJUSTED OP MARGINS
-44% Organic Growth	21.5%
Reported: -47% | M&A: 0% | FX: -3%	-2,430 bps y/y
Non-COVID Organic Growth: 3%	

- +DD ImmunoDx ex. China non-COVID organic growth
- +DD Non-COVID organic growth in Applied Genomics consumables offset by –DD decline in instruments
- +DD Neonatal performance offset by lighter Genomic lab volumes

2023 Financial Guidance

ADJ. REVENUE	**$2.90B - 2.94B**
	-11% to –13% reported
	Organic: -11% to -13%
	Non-COVID Organic: +7% to +9%
	COVID: $3 million (vs. $617M in 2022)
ADJUSTED OP. MARGIN	**30%**
ADJUSTED EPS	**$4.85 - $5.05**
	Adj. Net interest expense, other: ~80M
	Adjusted tax rate: 21%
	Average diluted share count: 126.0M



Revvity.com